Metamfetamine

Generic Name: Metamfetamine

Brand Names: Desoxyn

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₅N

CAS Number: 537-46-2

Unique Ingredient Identifier: 44RAL3456C

Background: Metamfetamine (methamphetamine) is a psychostimulant and sympathomimetic drug, and a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potential for addiction and abuse.

The FDA withdrew its approval for the use of all parenteral drug products containing methamphetamine hydrochloride, a metamfetamine salt.

Indication: For the treatment of Attention Deficit Disorder with Hyperactivity (ADHD) and exogenous obesity.

Associated Conditions: Attention Deficit Hyperactivity Disorder (ADHD), Narcolepsy, Refractory exogenous obesity

Clinical Trials

A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine

Phase 2

Not yet recruiting

Conditions: Methamphetamine Intoxication
Methamphetamine Disorders
Methamphetamine Abuse

Interventions: Drug: Methamphetamine
Drug: Sterile Saline
Drug: CS-1103

First Posted Date: 2024-12-06

Last Posted Date: 2025-05-04

Lead Sponsor: Clear Scientific, Inc.

Target Recruit Count: 40

Registration Number: NCT06721494

Locations: 🇺🇸
California Clinical Trials Medical Group, Glendale, California, United States

MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)

Phase 2

Not yet recruiting

Conditions: Obsessive-Compulsive Disorder

Interventions: Drug: 3,4-Methyl enedioxy methamphetamine
Drug: Methamphetamine
Behavioral: Cognitive Behavioral Therapy (CBT)

First Posted Date: 2023-03-24

Last Posted Date: 2025-02-25

Lead Sponsor: Carolyn Rodriguez

Target Recruit Count: 40

Registration Number: NCT05783817

Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function

Early Phase 1

Completed

Conditions: Social Behavior
Motivation
Stimulant Use
MDMA ('Ecstasy')

Interventions: Drug: MDMA
Drug: Methamphetamine
Drug: placebo oral tablet

First Posted Date: 2022-05-18

Last Posted Date: 2024-01-24

Lead Sponsor: University of Chicago

Target Recruit Count: 43

Registration Number: NCT05379959

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Brain Function and EEG

Early Phase 1

Completed

Conditions: Healthy
Mood

Interventions: Drug: Methamphetamine
Drug: Placebo

First Posted Date: 2021-08-12

Last Posted Date: 2024-01-24

Lead Sponsor: University of Chicago

Target Recruit Count: 40

Registration Number: NCT05003076

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Drugs Brain and Behavior (DDP)

Early Phase 1

Completed

Conditions: Stimulant Use

Interventions: Drug: Methamphetamine
Drug: placebo oral tablet

First Posted Date: 2020-11-24

Last Posted Date: 2025-01-09

Lead Sponsor: University of Chicago

Target Recruit Count: 138

Registration Number: NCT04642820

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Mirtazapine and Methamphetamine Drug-drug Interaction Study

Phase 1

Recruiting

Conditions: Methamphetamine Use Disorder
Drug Interaction
Cardiovascular Abnormalities

Interventions: Drug: Mirtazapine
Drug: Methamphetamine

First Posted Date: 2020-11-04

Last Posted Date: 2023-11-22

Lead Sponsor: San Francisco Department of Public Health

Target Recruit Count: 24

Registration Number: NCT04614584

Locations: 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸
San Francisco Department of Public Health, San Francisco, California, United States
🇺🇸
Substance Use Research Unit, San Francisco, California, United States

Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]

Phase 1

Completed

Conditions: Methamphetamine Use Disorder

Interventions: Drug: Methamphetamine
Drug: Methylphenidate
Drug: Placebo oral capsule
Drug: Duloxetine

First Posted Date: 2019-11-26

Last Posted Date: 2023-01-09

Lead Sponsor: Craig Rush

Target Recruit Count: 8

Registration Number: NCT04178993

Locations: 🇺🇸
University of Kentucky Medical Center, Lexington, Kentucky, United States
🇺🇸
University of Kentucky, Lexington, Kentucky, United States

Effects of Genotype on Resting State Connectivity During Methamphetamine Administration

Phase 4

Completed

Conditions: Methamphetamine-dependence

Interventions: Behavioral: Magnetic resonance imaging (MRI)
Drug: Methamphetamine Hydrochloride Tablets
Drug: Placebo oral tablet

First Posted Date: 2019-06-04

Last Posted Date: 2024-11-15

Lead Sponsor: Oregon Health and Science University

Target Recruit Count: 69

Registration Number: NCT03973489

Locations: 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸
Portland VA Medical Center, Portland, Oregon, United States